|Bid||4.0200 x 1000|
|Ask||4.0400 x 800|
|Day's Range||3.9800 - 4.2450|
|52 Week Range||2.3400 - 7.9900|
|Beta (5Y Monthly)||0.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 06, 2023 - Nov 10, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.80|
Subscribe to Yahoo Finance Plus to view Fair Value for DCTH
Let’s take a moment to talk about opportunity, share price, and risk/reward considerations. These are some of the factors investors must consider when moving into penny stocks – and we haven’t even touched on the fundamental soundness of the company or its business model. Penny stocks – as their name suggests, they once traded for just a pennies per share, but these days are considered those equities trading at less than $5 – are a challenging market niche. The penny stock critics make valid poi
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the details of an oral presentation by independent investigators on September 9, 2023 at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting held in Copenhagen, Denmark.
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C Wainwright 25th Annual Global Investor Conference. Delcath CEO, Gerard Michel will present on September 13 at 11:00 AM ET.